Biomarker Assay Articles & Analysis
11 news found
” Protheragen’s rare disease diagnostic development services cover in vitro diagnostic (IVD) product development, point-of-care test (POCT) development, laboratory animal models, and companion diagnostic development. By leveraging its expertise in assay development, biomarker identification, and regulatory compliance, Protheragen aims to advance ...
With state-of-the-art instrumentation and a dedication to scientific rigor, Alfa Chemistry is able to deliver macromolecular drug bioanalysis, small molecule drug bioanalysis, biomarker assay, aggregate analysis, luminescence testing, and affinity capture elution analytical services. ...
Biomarker detection can provide insight into the mechanism of action or resistance of new drugs in disease models. ...
Fox Foundation in 2015 toward pre-clinical optimization of anle138b and biomarker assay development and now the foundation will support this first-in-patient study. ...
More than 1.7 million people in the U.S. are diagnosed with sepsis each year.2,3,4 Thermo Fisher is committed to providing exceptional laboratory tools to assess the risk of bacterial infection relating to sepsis with the B·R·A·H·M·S PCT (Procalcitonin) biomarker assay. The results of the assay are intended to ...
Amaral is working with a company to develop an assay for biomarkers associated with certain subtypes of ASD. Stemina Biomarker Discovery of Madison, WI, and its diagnostic division NeuroPointDX, recently released results showing that it had identified an alteration in amino acid metabolism in nearly one in five children with autism, and had ...
’s HCC Panel is a unique algorithm-driven biomarker panel that takes advantage of the Company’s patented fucosylated biomarker technology. ...
Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry. ...
Glycotest, Inc. announced today that a Japanese patent protecting fucosylated kininogen—a key biomarker in the Company’s lead HCC Panel test for earlystage liver cancer—has been granted. ...
Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry. ...
Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry. ...